<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03912181</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0864</org_study_id>
    <nct_id>NCT03912181</nct_id>
  </id_info>
  <brief_title>Medical Complications in Familial and Multifactorial Chylomicronaemia Syndromes</brief_title>
  <acronym>ESTHYM</acronym>
  <official_title>Medical Complications in Familial and Multifactorial Chylomicronaemia Syndromes From a 10 Year Follow-up Linking Datasets Between Patient Medical Records and Patient Claims: the ESTHYM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective, systematic study of reimbursed healthcare costs over a 10 year period in
      patients suffering from Familial Chylomicronaemia Syndromes (FCS) or Multifactorial
      Chylomicronaemia Syndromes (MCS) in order to establish the relative healthcare burden of both
      syndromes by linking the Hospices Civils de Lyon (HCL) registry of FCS or MCS patients and
      data obtained from FCS or MCS patients followed in Paris, Nantes and Lyon to the French
      National Health System (NHS) healthcare claims database, the Système National d'Information
      Inter-Régimes de l'Assurance Maladie (SNIIR-AM).

      A probabilistic approach will be used to link databases. This linkage will be based on the
      following variables: age, gender, date of discharge of any hospitalization, date of any
      imaging procedure.

      This study will help to describe, in real life, the management of severe hyperglyceridaemia
      in France. In addition, the descriptive results will help obtain a better understanding of
      the patients suffering from this disease, the burden of the disease and the healthcare
      consumption linked to this disease. Even if this consumption of care has been relatively
      unexplored until this point, it is not negligible. The potential of merging genomics and
      claims data for cardiovascular research could help to identify ways to optimize disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">February 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Acute Pancreatitis, Ischemic Cardiovascular Disease and any additional co-morbidity</measure>
    <time_frame>2006-2016 (10 year follow-up)</time_frame>
    <description>outcomes obtained by anonymous linkage with the Système National des Données de Santé (SNDS) national data base of any health resource consumption (&gt; 40x106 subjects exhaustive compilation, linkage with Programme de médicalisation des systèmes d'information (PMSI) (diagnosis data base) and death registry)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">140</enrollment>
  <condition>Familial Chylomicronemia Syndrome</condition>
  <condition>Multifactorial Chylomicronemia Syndrome</condition>
  <arm_group>
    <arm_group_label>Familial chylomicronaemia syndrome (FCS)</arm_group_label>
    <description>Patient homozygous or compound heterozygous mutation in lipoprotein lipase (LPL) gene
Patient homozygous or compound heterozygous mutation in any Apolipoprotein A5 (Apo A5), glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2), genes and heterozygous (het) mutation in LPL gene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multifactorial chylomicronemia syndrome</arm_group_label>
    <description>Patient with heterozygous mutation in lipoprotein lipase (LPL) , Apolipoprotein A5 (Apo AV), GPI HBP1, LMF1, ApoC2 genes and any additional combination of functional variant
Patient with any additional combination of functional variant in LPL gene Apo AV, glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2) genes</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients male or female at least 18 years old having genetically documented familial or
        multifactorial chylomicronaemia syndrome.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  genetically documented FCS

          -  genetically documented MCS

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Moulin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type I</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

